The Patent Finder

Caribou Biosciences, Inc.

67 patents currently held · Updated Nov 21, 2026
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Dec 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 25, 2026
    The maintenance fee for Engineered Cascade Components and Cascade Complexes (US 10,329,547) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
  • 2 fees due Apr 8 to 29, 2027 · next Apr 8
  • 2 fees due Jun 10 to 30, 2027 · next Jun 10
  • 1 fee due Aug 16, 2027
    The maintenance fee for Compositions and Methods of Nucleic Acid-Targeting Nucleic Acids (US 9,260,752) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
  • 4 fees due Sep 17 to 26, 2027 · next Sep 17

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,885,026Modified Cascade Ribonucleoproteins and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,435,678Modified Cascade Ribonucleoproteins and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,711,257Modified Cascade Ribonucleoproteins and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 10,954,498Modified Cascade Ribonucleoproteins and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,939,604Modified Cascade Ribonucleoproteins and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,260,752Compositions and Methods of Nucleic Acid-Targeting Nucleic Acids
In force
 · High confidence
In forceHigh confidence
US 9,410,198Compositions and Methods of Nucleic Acid-Targeting Nucleic Acids
In force
 · High confidence
In forceHigh confidence
US 9,725,714Compositions And Methods Of Nucleic Acid-Targeting Nucleic Acids
In force
 · High confidence
In forceHigh confidence
US 9,803,194Compositions And Methods Of Nucleic Acid-Targeting Nucleic Acids
In force
 · High confidence
In forceHigh confidence
US 9,809,814Compositions And Methods Of Nucleic Acid-Targeting Nucleic Acids
In force
 · High confidence
In forceHigh confidence
10 of 67 patents shown.
Pro members see all 67.
Pro members: see all 67 patents
Also on record, not counted in the 67: 5 patents in force now held by others · 2 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

15 pending · 16 abandoned · 2 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited